

November 12, 1969

Dr. Michael L. Grozier
Associate Clinical Research Director
The Squibb Institute for Medical Research
New Brunswick, New Jersey 08903

Dear Dr. Grozier:

We have reviewed the clinical records and the summaries of forty patients in a cross-over fluphenazine decanoate - fluphenazine enanthate study completed in our laboratories in 1968. The report previously submitted to the conference at Sitges included 62 patients treated with decanoate. We began our study with decanoate and many of the early cases suffered secondary effects, in part related to the trials by the staff in obtaining their experience. The data of the crossover group will be more comparable and a more representative picture of the secondary effects is shown on the attached table. It is apparent that the compounds are quite similar in their effects in this population.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp

November 12, 1969

FLUPHENAZINE DECANOATE - ENANTHATE

Crossover 1967-68

	<u>Raw Data</u>		<u>Summary</u>	
	FD	FE	FD	FE
Parkinsonism	4	3	5	2
Akathesia & Restlessness	4	5	4	4
Other	5	9	3	5
Sum	13	17	12	11
% incidence	32%	42%	30%	27%

N = 40